Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0298254 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Adeel Ajwad Butt und 2 weiteren Autor:innen. Beteiligte Einrichtung: VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States of America. Hauptthemen laut MEDLINE: Ritonavir, Hydroxylamines, Disease Progression, Cytidine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Department of Veterans Affairs (VA) Informatics and Computing Infrastructure.
Abstract (Originalsprache)
Background
In randomized controlled trials, Nirmatrelvir/ritonavir (NMV/r) and Molnupiravir (MPV) reduced the risk of severe/fatal COVID-19 disease. Real-world data are limited, particularly studies directly comparing the two agents.
Methods
Using the VA National COVID-19 database, we identified previously uninfected, non-hospitalized individuals with COVID-19 with ≥1 risk factor for disease progression who were prescribed either NMV/r or MPV within 3 days of a positive test. We used inverse probability of treatment weights (IPTW) to account for providers’ preferences for a specific treatment. Absolute risk difference (ARD) with 95% confidence intervals were determined for those treated with NMV/r vs. MPV. The primary outcome was hospitalization or death within 30 days of treatment prescription using the IPTW approach. Analyses were repeated using propensity-score matched groups.
Results
Between January 1 and November 30, 2022, 9,180 individuals were eligible for inclusion (6,592 prescribed NMV/r; 2,454 prescribed MPV). The ARD for hospitalization/death for NMV/r vs MPV was -0.25 (95% CI -0.79 to 0.28). There was no statistically significant difference in ARD among strata by age, race, comorbidities, or symptoms at baseline. Kaplan-Meier curves did not demonstrate a difference between the two groups (p-value = 0.6). Analysis of the propensity-score matched cohort yielded similar results (ARD for NMV/r vs. MPV -0.9, 95% CI -2.02 to 0.23). Additional analyses showed no difference for development of severe/critical/fatal disease by treatment group.
Conclusion
We found no significant difference in short term risk of hospitalization or death among at-risk individuals with COVID-19 treated with either NMV/r or MPV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States of America.
- Weill Cornell Medicine, New York, New York, United States of America.
- Weill Cornell Medicine Qatar, Doha, Qatar.
- Hamad Medical Corporation, Doha, Qatar.
- University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
ORCID-Profile: Adeel Ajwad Butt
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- Department of Veterans Affairs (VA) Informatics and Computing Infrastructure
Zitieren
APA
Butt, A. A., Yan, P., & Shaikh, O. S. (2024). Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression. PLOS ONE. https://doi.org/10.1371/journal.pone.0298254
Vancouver
Butt AA, Yan P, Shaikh OS. Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression. PLOS ONE. 2024. doi:10.1371/journal.pone.0298254
BibTeX
@article{Butt2024,
author = {Butt, Adeel Ajwad and Yan, Peng and Shaikh, Obaid S},
title = {Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0298254}
}
EUVIMED